Viking's VK2735 Maintenance Data (97% Retention) Sparked a 36% Spike — Then a $575M Dilutive Raise Landed
Viking Therapeutics delivered the cycle's standout clinical readout from a mid-cap: Phase 2 maintenance data for subcutaneous VK2735 (dual GLP-1/GIP agonist), presented September 22, 2026. Patients lost an average of 16–19% of body weight over 21 weeks on weekly dosing (vs. 0.1% placebo), then switched to less frequent dosing: "Those taking the medicine every other week maintained up to 97% of their weight loss three months after switching to this new dosing schedule, and patients taking it monthly maintained up to 90%... Those taking a placebo maintained only 61% of their weight loss over the same period." The strategic pitch is dosing convenience — 12 or 26 doses per year instead of 52 — and a potential landing spot for patients worried about regaining weight after stopping Zepbound or Wegovy, though the data cover only patients who lost weight on VK2735 itself, and the study was small (~180 patients, proof of concept).
The stock surged 36% on the news, then round-tripped: VKTX closed at $29.94 on Oct 2, down 27.2% over three months and 28.9% below its 52-week high, with 9.0% 20-day volatility. The reason is financing: Viking closed a $575.0M stock-and-convertible-note offering on September 28 to fund VK2735 and VK3019, diluting holders days after the data pop. The balance sheet context explains why — as of June 30 Viking had $125.8M cash against a $125.2M quarterly operating cash burn (Q2 net loss $128.0M), so the raise roughly quintuples the runway into Phase 3.
Pipeline catalysts ahead: two Phase 3 trials of injectable VK2735 are ongoing (obesity, diabetes), an oral VK2735 Phase 3 is slated to start by end of 2026 (standing watch), an oral-maintenance substudy of this same maintenance design is planned, and the VK3019 amylin/calcitonin dual agonist is in Phase 1 SAD (standing watch). Retail chatter about buyout interest circulated after the raise but nothing is confirmed. Viking's maintenance win lands in the same week Lilly's Foundayo accelerated and Novo's pill stalled (see Oral GLP-1 Battle Flips: Foundayo Surges 21% to 64K Weekly Scripts While Wegovy Pill Stalls at ~182K) — evidence the market still rewards differentiated clinical mechanisms even as it starves undifferentiated oral GLP-1 pure-plays like GPCR (down 41.6% in a month, see EASD 2026: Amylin Combos Emerge as the Next Frontier; Lilly Leans on Indirect Head-to-Head Claims).